Paris-based Sanofi (Nasdaq:SNY) is the fastest company to reduce insulin prices. The pharmaceutical behemoth said it would cut  the list price of Lantus (insulin glargine injection) by 78%. Lantus is its most commonly prescribed insulin in the U.S. Moreover, Sanofi will implement a $35 cap on out-of-pocket expenses for users of the insulin. Sanofi has also…

Sanofi announced that it agreed to acquire Provention Bio, which develops therapeutics for immune-mediated diseases, for approximately $2.9 billion. Paris, France-based Sanofi agreed to acquire Provention Bio for $25 per share in cash. If the companies complete the acquisition, Sanofi expects a wholly-owned subsidiary to merge with and into Provention Bio. It intends to fund…

Sanofi (Euronext:SAN and Nasdaq:SNY) has announced that it has moved into its new international headquarters to Paris’s 17th arrondissement neighborhood, which is located on the right bank of the Seine River.   The news headquarters, situated at 46-48 Avenue de la Grande Armée, was designed to promote novel ways to collaborate.  Measuring 9,000 m² in area,…

Digital transformation has been a buzzword among enterprise companies and business consultants for the past roughly five years. Conservative industries such as the pharmaceutical sector, however, have had a broadly tentative attitude toward transformation. The situation began to change during the pandemic, however. Now, Sanofi (Nasdaq:SNY) has launched an AI-focused digital accelerator focused on developing…

Sanofi announced today that it is officially opening its new 900,000-square-foot campus at Cambridge Crossing in Cambridge, Massachusetts. The new campus brings together 2,500 Sanofi Massachusetts-based employees in a shared space. The goal is to improve collaboration between R&D, Medical, and the Specialty Care business unit — and grow a science-centered, patient-focused culture. The Paris-based…

French drugmaker Sanofi (Nasdaq:SNY) said it would spend €935 million (about $1.1 billion) between 2022 and 2026 to produce mRNA-based vaccines. That funding is part of a larger €2 billion (about $2.4 billion) initiative to accelerate its mRNA development capability, Sanofi explained on its French-language website. The company intends to use the funds to ramp…

Rapid-acting insulin specialist MannKind Corp. (NSDQ:MNKD) has enrolled the first pediatric patient in its INHALE-1 study evaluating its Afrezza (Technosphere Insulin) with basal insulin versus multiple daily injections of insulin. The study will enroll participants aged four to 17 with type 1 or type 2 diabetes. Afrezza first won FDA approval in 2014, and MannKind…

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead. That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data…

Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance.  Now ranked eighth overall, the pharma industry came in just ahead of…

Sanofi announced today that it will spend €600 million ($685 million) on a new plant in Toronto to produce its differentiated influenza vaccines. The Paris-based pharma giant’s Fluzone high-dose quadrivalent influenza vaccine has four times more antigen than a standard-dose vaccine. The vaccine’s creators specifically designed it to provide superior protection against influenza for older…